Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data.
Fiche publication
Date publication
décembre 2020
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr DALAC Sophie, Dr GRANEL-BROCARD Florence
Tous les auteurs :
Di Filippo Y, Dalle S, Mortier L, Dereure O, Dalac S, Dutriaux C, Leccia MT, Legoupil D, Saiag P, Brunet-Possenti F, Arnnault JP, Maubec E, Granel-Brocard F, De Quatrebarbes J, Aubin F, Lesimple T, Beylot-Barry M, Stoebner PE, Dupuy A, Stephan A, Grob JJ, Lefevre W, Oriano B, Allayous C, Lebbé C, Montaudié H
Lien Pubmed
Résumé
The "obesity paradox" suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events. This study assesses whether body mass index is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy.
Mots clés
body mass index, clinical outcomes, immunotherapy, melanoma, systemic therapy, targeted therapy
Référence
Ann Oncol. 2020 Dec 29;: